Panels at Digital RESI November

2 Dec

By Rory McCann, Marketing Manager & Conference Producer, LSN

Panel discussions are a popular feature at RESI partnering events. They are valuable tools for entrepreneurs to gather insight from those who are further up the road they are walking and can illuminate what hurdles they may encounter on their own fundraising journey. As the team at Life Science Nation prepares panels for Digital RESI JPM, we want to take the opportunity to share a sample of panel discussions at the past event.

Do you or a colleague have their own experience to share at Digital RESI JPM? Let us know and check out our lineup for next month’s virtual event. Looking to connect with investors and learn from colleagues in your industry? Sign up today to save $200 on early-bird rates!

Clinical & Research Data

Clinical & Research Data

Tales from the Road (RESI)

Tales from the Road (RESI)

Women in Age-Tech

Women in Age-Tech

Impact Investors

Impact Investors

Hot Investor Mandate: New US Fund of Asia-Based Healthcare VC Seeks USA & Europe Companies in Therapeutics, Medical Device, and Diagnostics Sectors

2 Dec

A new founded US fund of an Asia-based healthcare-focused venture capital firm. The firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to work will entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: European Investment Firm Invests in Novel Therapies in Oncology and Genetic Diseases, Invests Up to $30M Over the Company’s Lifespan

2 Dec

A global investor, headquartered in Europe that was previously focused on oncology has expanded their investments to genetic diseases with its new fund. The firm makes selective investments in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards. The investment size will vary, and it can invest $25-30M over the lifetime of the companies. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Seeks Medical Device & Diagnostics Investments Across the USA, Prefers Companies with Working Prototypes or Strong Proof-of-Concept

2 Dec

A Venture Capital firm based in the USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA VC Invests in Therapeutics & Medical Device Technologies, With Strongest Interest in Therapeutics Solutions Targeting Unmet Medical Need

2 Dec

A Venture Capital firm based in USA manages 5 funds. With the latest fund, the firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6-8 million over the life of the investment. The firm generally looks for companies with lead assets that can reach a high value inflection point in 3-4 years. The firm will consider companies in North America.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics which is the firms primary focus, companies with an asset anywhere from preclinical with positive animal data to Phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Let Your Voice Be Heard at Digital RESI JPM

18 Nov

By Rory McCann, Marketing Manager & Conference Producer, LSN

As Digital RESI November closes today, the team at Life Science Nation is looking ahead to Digital RESI JPM, January 11-13, 2022. In addition to RESI’s powerful partnering system, the virtual panels are a highlight for investors and fundraising entrepreneurs alike. RESI panels feature industry innovators and subject matter experts to discuss navigating the early-stage ecosystem within life science and healthcare, tackling topics relevant to fundraising and company-building.

Is there a topic you’d like to see at Digital RESI JPM? Would you recommend a particular industry expert or prolific investor to speak to fundraising in this space? We want to hear from you and highlight the issues and stories that are most meaningful to the RESI community. Send your suggestions to RESI@lifesciencenation.com and sign up for Digital RESI JPM by Friday, November 28 to save $300!

Digital RESI JPM Pitch Applications Open

18 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Today is the last day of the Digital RESI November Innovator’s Pitch Challenge. If you missed your opportunity to pitch to relevant investors seeking opportunities in your space, Digital RESI JPM, January 11-13, 2022 is right around the corner! Join us at the biggest virtual fundraising event of the year and submit your application the the Digital RESI JPM Innovator’s Pitch Challenge.

What is it?

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a $800 pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

How Does it Work?

Pitching companies will have a dedicated webpage on the Live Agenda, which greatly increases visibility to investors. Prior to the live pitch session, the investor panel will review submitted pitch materials and prepare questions.

Each company has approximately 10 minutes set aside for their participation. Each session is judged by a panel of investors who have expressed interest in the sector(s) highlighted in the session. During the session, the pitching company delivers a brief (~1 minute) elevator pitch, and saves the rest of their time for investors’ questions, feedback and commentary. The session is open to all registered RESI attendees.

IPC-EXAMPLE-Page

Who Should Apply?

Early-stage life science companies actively raising seed capital (25K-2MM), Series A (2MM-10MM), or Series B (10MM-50MM) use the IPC to get in front of the panel of qualified investor judges in their market segment and pitch their company and product. Early-stage companies are encouraged to submit an application, along with a pitch deck and an executive summary. Once selected to pitch, companies can submit their video and supplemental materials for investors to review prior to the live session.

Apply for IPC with Icon

← Older Entries
Newer Entries →